Enhanced Antitumor Efficacy and Reduced Myelosuppression by a Supramolecular Complex Composed of Azocalix[4]arene and Sunitinib
- 18 November 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (22) , 24456-24468
Abstract
Antiangiogenic therapy, which inhibits tumor growth by blocking oxygen and nutrition supply, represents a promising strategy for antineoplastic therapy. However, the widespread biodistribution of antiangiogenic agents often leads to off-target toxicities, including hematotoxicity and myelosuppression. In this study, we demonstrated that the sunitinib@mannose-modified azocalix[4]arene (ST@ManAC4A) complex exhibited favorable tumor-targeting capabilities, hypoxia-responsive drug release, and effective accumulation at the tumor site, thus enhancing antiproliferative efficacy while alleviating thrombocytopenia and myelosuppression. The complex exhibited robust antitumor activity in both cellular and in vivo assays. Additionally, histopathological, immunohistochemical, and bone marrow analyses demonstrated that ST@ManAC4A enhanced antiproliferation, apoptosis, and antiangiogenesis while alleviating thrombocytopenia and platelet-related myelosuppression. These findings underscore the potential of the mannose-modified supramolecular host-guest complex as a versatile form for improving chemotherapy outcomes. By enabling efficient drug loading and precision targeting, this approach offers a promising strategy to enhance therapeutic efficacy while minimizing off-target toxicities, addressing a critical challenge in cancer treatment.Keywords
Funding Information
- Natural Science Foundation of Hebei Province (22567632H, B2023201108, B2024201007, B2025201113)
- Department of Education of Hebei Province (BJ2025040, JZX2024018)
- Hebei University (521100223250)
- National Natural Science Foundation of China (22401071, U20A20259)
- Foundation of Hebei University (050001-513300202015)
This publication has 68 references indexed in Scilit:
- Peptide‐Drug Conjugate for Therapeutic Reprogramming of Tumor‐Associated Macrophages in Breast CancerAdvanced Science, 2025
- Enhanced subacute ischemic stroke treatment via multistage drug delivery system design for combination therapyScience China Chemistry, 2025
- A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2‐Positive Breast CancerAdvanced Science, 2024
- Glycol‐Split Heparin‐Linked Prodrug Nanoparticles Target the Mitochondrion Apparatus for Cancer Metastasis TreatmentSmall, 2023
- Myelosuppression Alleviation and Hematopoietic Regeneration by Tetrahedral‐Framework Nucleic‐Acid Nanostructures Functionalized with Osteogenic Growth PeptideAdvanced Science, 2022
- Light‐Triggered Efficient Sequential Drug Delivery of Biomimetic Nanosystem for Multimodal Chemo‐, Antiangiogenic, and Anti‐MDSC Therapy in MelanomaAdvanced Materials, 2022
- Polyamine‐Responsive Morphological Transformation of a Supramolecular Peptide for Specific Drug Accumulation and Retention in Cancer CellsSmall, 2021
- Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)—development and in-vitro efficacyDrug Delivery and Translational Research, 2021
- Supramolecular Polymerization‐Induced Nanoassemblies for Self‐Augmented Cascade Chemotherapy and Chemodynamic Therapy of TumorAngewandte Chemie International Edition, 2021
- Noncovalent Targeting of Nanocarriers to Immune Cells with Polyphosphoester‐Based Surfactants in Human Blood PlasmaAdvanced Science, 2019